Bellevue Group’s Viking Therapeutics VKTX Stock Holding History

Bellevue Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,665	Closed	-$2.42M	–	193
2025 Q4	$2.42M	Sell	68,665 -7,417	-10%	-$263K	0.05%	92
2025 Q3	$2M	Buy	+76,082	New	+$2.27M	0.04%	97
2025 Q1	–	Sell	-12,939	Closed	-$521K	–	168
2024 Q4	$521K	Sell	12,939 -3,240	-20%	-$185K	0.01%	125
2024 Q3	$1.02M	Buy	16,179 +11,779	+268%	+$691K	0.02%	118
2024 Q2	$233K	Sell	4,400 -1,000	-19%	-$65.6K	﹤0.01%	144
2024 Q1	$443K	Sell	5,400 -12,100	-69%	-$538K	0.01%	134
2023 Q4	$326K	Buy	+17,500	New	+$229K	0.01%	146
2023 Q3	–	Sell	-33,000	Closed	-$535K	–	164
2023 Q2	$535K	Buy	+33,000	New	+$691K	0.01%	142
2019 Q3	–	Sell	-96,000	Closed	-$797K	–	221
2019 Q2	$797K	Buy	+96,000	New	+$820K	0.01%	143

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bellevue Group's VKTX Position: Q1 2026 in Review

Bellevue Group sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 68,665 shares — an estimated $2.42M sold.

Bellevue Group first reported a position in VKTX in Q2 2019 and held it in 9 quarters. The position peaked at $2.42M in Q4 2025. 414 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Bellevue Group reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 68,665 Viking Therapeutics shares in Q1 2026, an estimated $2.42M.
Bellevue Group first reported a position in Viking Therapeutics in Q2 2019 and held it in 9 quarters.
Bellevue Group's Viking Therapeutics position peaked at $2.42M in Q4 2025.
414 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.